US11400186B2 - Drug delivery system for the delivery of antiviral agents - Google Patents

Drug delivery system for the delivery of antiviral agents Download PDF

Info

Publication number
US11400186B2
US11400186B2 US16/300,121 US201716300121A US11400186B2 US 11400186 B2 US11400186 B2 US 11400186B2 US 201716300121 A US201716300121 A US 201716300121A US 11400186 B2 US11400186 B2 US 11400186B2
Authority
US
United States
Prior art keywords
deoxyadenosine
ethynyl
fluoro
drug delivery
vinyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/300,121
Other languages
English (en)
Other versions
US20190388590A1 (en
Inventor
Stephanie Elizabeth Barrett
Marian E. Gindy
Li Li
Ryan S. Teller
Seth P. Forster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Priority to US16/300,121 priority Critical patent/US11400186B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GINDY, MARIAN E., BARRETT, Stephanie Elizabeth, FORSTER, Seth P., LI, LI, TELLER, Ryan S.
Publication of US20190388590A1 publication Critical patent/US20190388590A1/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of US11400186B2 publication Critical patent/US11400186B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • drugs listed in the table can be used in a salt form; e.g., abacavir sulfate, delavirdine mesylate, indinavir sulfate, atazanavir sulfate, nelfinavir mesylate, saquinavir mesylate.
  • the in vitro release rate of 4′-ethynyl-2-fluoro-2′-deoxyadenosine was determined by incubating the implants segments, approximately 1 cm in length, in a glass vial containing phosphate buffered saline (PBS) at 37° C., and 50 rpm shaking in an Innova 42 incubator.
  • PBS phosphate buffered saline
  • the volume of PBS was sufficient to maintain sink conditions. Sink conditions are defined as the drug concentration maintained at or below 1 ⁇ 3 of the maximum solubility (drug concentration ⁇ 0.45 mg/mL in PBS at 37° C.). Samples were removed (0.5 mL) at selected time points, and centrifuged at 20,800 ⁇ g for 8 min.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US16/300,121 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents Active US11400186B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/300,121 US11400186B2 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662335319P 2016-05-12 2016-05-12
US16/300,121 US11400186B2 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents
PCT/US2017/031493 WO2017196697A1 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents

Publications (2)

Publication Number Publication Date
US20190388590A1 US20190388590A1 (en) 2019-12-26
US11400186B2 true US11400186B2 (en) 2022-08-02

Family

ID=60266868

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/300,121 Active US11400186B2 (en) 2016-05-12 2017-05-08 Drug delivery system for the delivery of antiviral agents

Country Status (11)

Country Link
US (1) US11400186B2 (es)
EP (1) EP3454868A4 (es)
JP (1) JP6934019B2 (es)
KR (1) KR102272235B1 (es)
CN (2) CN115624564A (es)
AU (1) AU2017263253B2 (es)
BR (1) BR112018072883B1 (es)
CA (1) CA3023364A1 (es)
MX (1) MX2018013662A (es)
RU (1) RU2755130C2 (es)
WO (1) WO2017196697A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220331350A1 (en) * 2016-02-12 2022-10-20 Merck Sharp & Dohme Corp. Methods for treatment and prophylaxis of hiv and aids

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419817B2 (en) 2017-04-10 2022-08-23 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
JOP20220033A1 (ar) * 2019-08-13 2023-01-30 Merck Sharp & Dohme نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات
AU2021268584A1 (en) * 2020-05-05 2022-12-01 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2168257A (en) * 1984-12-05 1986-06-18 Lrc Products Intra-vaginal contraceptives
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US6262137B1 (en) * 1996-11-15 2001-07-17 Sentinel Products Corp. Polymer articles including maleic anhydride and ethylene-vinyl acetate copolymers
US20040175426A1 (en) 2003-01-24 2004-09-09 Control Delivery Systems, Inc. Controlled release of highly soluble agents
WO2004103336A2 (en) * 2003-05-23 2004-12-02 Akzo Nobel N.V. Drug delivery system
US20100080830A1 (en) 2000-04-26 2010-04-01 Psivida Inc. Systemic delivery of antiviral agents
US20110206745A1 (en) 2008-06-25 2011-08-25 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
US20130195950A1 (en) 2010-03-16 2013-08-01 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US8722037B2 (en) * 2004-03-19 2014-05-13 Meck Sharp & Dohme B.V. X-ray visible drug delivery device
WO2014123880A1 (en) * 2013-02-05 2014-08-14 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US8835615B2 (en) * 2007-07-16 2014-09-16 Junbiao Chang 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof
US20150051167A1 (en) 2012-03-21 2015-02-19 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015086489A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US20150297553A1 (en) 2013-03-11 2015-10-22 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
WO2016149561A1 (en) 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
WO2017222903A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
WO2018057408A1 (en) 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
WO2018191093A1 (en) 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601835A (en) 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5114719A (en) 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
KR20100120243A (ko) * 2002-05-07 2010-11-12 피시비다 유에스 인코포레이티드 약물 전달 장치를 형성하는 공정
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CA2713105C (en) * 2008-01-25 2016-06-07 Chimerix, Inc. Methods of treating viral infections
WO2009126293A2 (en) 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
SG196774A1 (en) * 2008-12-24 2014-02-13 Tibotec Pharm Ltd Implantable devices for treating hiv

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2168257A (en) * 1984-12-05 1986-06-18 Lrc Products Intra-vaginal contraceptives
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
RU2157246C2 (ru) 1994-06-23 2000-10-10 Акксиа Техноложиз Подкожный имплантант
US6262137B1 (en) * 1996-11-15 2001-07-17 Sentinel Products Corp. Polymer articles including maleic anhydride and ethylene-vinyl acetate copolymers
US20100080830A1 (en) 2000-04-26 2010-04-01 Psivida Inc. Systemic delivery of antiviral agents
US20040175426A1 (en) 2003-01-24 2004-09-09 Control Delivery Systems, Inc. Controlled release of highly soluble agents
WO2004103336A2 (en) * 2003-05-23 2004-12-02 Akzo Nobel N.V. Drug delivery system
US8722037B2 (en) * 2004-03-19 2014-05-13 Meck Sharp & Dohme B.V. X-ray visible drug delivery device
US8835615B2 (en) * 2007-07-16 2014-09-16 Junbiao Chang 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof
US20110206745A1 (en) 2008-06-25 2011-08-25 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
US20130195950A1 (en) 2010-03-16 2013-08-01 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US20150051167A1 (en) 2012-03-21 2015-02-19 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014123880A1 (en) * 2013-02-05 2014-08-14 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US20150297553A1 (en) 2013-03-11 2015-10-22 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
WO2015086489A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
WO2016149561A1 (en) 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
WO2017222903A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
WO2018057408A1 (en) 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
WO2018191093A1 (en) 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Baert, L. et al., Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment, European Journal of Pharmaceutics and Biopharmaceutics, 2009, 502-208, 72 (3).
Barrett, Stephanie et al., Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention, Antimicrobial Agents and Chemotherapy, 2018, 1-13, vol. 62(10), e01058-18.
Brazel, Christopher et al., Mechanisms of solute and drug transport in relaxing, swellable, hydrophilic glassy polymers, Polymer, 1999, 3383-3398, 40.
Grigoreva, M.V., Polymer systems with the controlled release of biologically active compounds, Biotechnologia Acta, 2011, 9-23 (English translation pp. 1-31), 4(2).
Grigoreva, M.V., Polymer systems with the controlled release of biologically active compounds, Biotechnologia Acta, 2011, 9-23, 4(2).
Gunawardana et al (Antimicrobial Agents and Chemotherapy 59:3913-3919, 2015) (Year: 2015). *
Gunawardana, M. et al., Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Impant for HIV Prophylaxis, Antimicrob. Agents Chemother., 2015, 3913-3919, 59 (7).
International Search Report and Written Opinion for PCT/2017/031493, dated Aug. 15, 2017, 8 pages.
Karmon, S.L et al., Next-Generation Integrase Inhibitors Where to After Raltegravir, Drugs, 2013, 213-228, 73 (3).
Kleppner et al (J Pharmacy and Pharmacol 58:295-302, 2006) (Year: 2006). *
Rajoli, R.K.R. et al., Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV, Clinical Pharmacokinetics, 2015, 639-650, 54 (6).
Ramirez Garcia, P. et al., Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS, The Journal of Association of Nurses in AIDS Care : JANAC, 2003, 37-45, 14 (4).
Reyes (Innovative Uses of EVA Polymers for Advancing Healthcare, 2014) (Year: 2014). *
Spreen, W.R. et al., Long-acting injectable antiretrovirals for HIV treatment and prevention, Current Opinion in HIV and AIDS, 2013, 565-571, 8 (6).
Supplementary European Search Report and Written Opinion for 17796613.2, dated Nov. 20, 2019, 9 pages.
Sysuev, B.B et al., Current research and development of innovative dosage forms and their modifications, Bulletin of Volgogradskyi State Medical University, 2014, 7-12 (English translation pp. 1-13), 4(52).
Sysuev, B.B et al., Current research and development of innovative dosage forms and their modifications, Bulletin of Volgogradskyi State Medical University, 2014, 7-12, 4(52).
Van't Klooster G. et al., Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation, Antimicrobial Agents and Chemotherapy, 2010, 2042-2050, 54 (5).
Whetten, K et al., Trauma, mental health, distrust, and stigma among HIV-Positive persons: Implications for effective care., Psychosomatic Medicine, 2008, 70.
Williams, J. et al., Long-acting parenteral nanoforulated antiretroviral therapy: interest and attitudes of HIV-infected patients, Nanomedicine, 2013, 1807-1813, 8 (11).
Zhang et al (Drug Development and Industrial Pharmacy 40(8):1101-1111, 2014) (Year: 2014). *
Zhang, Wei et al., Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention, Drug Development and Industrial Pharmacy, 2014, 1101-1111, 40:8.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220331350A1 (en) * 2016-02-12 2022-10-20 Merck Sharp & Dohme Corp. Methods for treatment and prophylaxis of hiv and aids

Also Published As

Publication number Publication date
RU2018141823A (ru) 2020-06-15
BR112018072883A2 (pt) 2019-03-06
CN115624564A (zh) 2023-01-20
WO2017196697A1 (en) 2017-11-16
JP2019514992A (ja) 2019-06-06
JP6934019B2 (ja) 2021-09-08
BR112018072883A8 (pt) 2023-01-10
CA3023364A1 (en) 2017-11-16
KR20190005931A (ko) 2019-01-16
RU2755130C2 (ru) 2021-09-13
MX2018013662A (es) 2019-03-01
EP3454868A4 (en) 2019-12-18
RU2018141823A3 (es) 2020-09-10
EP3454868A1 (en) 2019-03-20
CN109069526A (zh) 2018-12-21
AU2017263253A1 (en) 2018-10-25
AU2017263253B2 (en) 2022-04-14
BR112018072883B1 (pt) 2023-01-17
KR102272235B1 (ko) 2021-07-01
US20190388590A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
US11400186B2 (en) Drug delivery system for the delivery of antiviral agents
US20210186867A1 (en) Drug delivery system for the delivery of antiviral agents
ES2898348T3 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
RU2678695C2 (ru) Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита
US11419817B2 (en) Drug delivery system for the delivery of antiviral agents
KR20170056702A (ko) 지효성 약제학적 조성물
KR102286386B1 (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
EP3515438B1 (en) Drug delivery system for the delivery of integrase inhibitors
US20230149296A1 (en) Drug delivery system for the delivery of antiviral agents and contraceptives
US20220362277A1 (en) Drug delivery system for the delivery of antiviral agents
US20230310309A1 (en) Injectable depot compositions for the delivery of antiviral agents
US20150141376A1 (en) Pharmaceutical compositions of anti-viral compounds and process for preparation thereof
KR101499867B1 (ko) 활성 성분 (i) 함유 조성물 및 이의 제조 방법
US20030004130A1 (en) Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
WO2014159814A1 (en) Formulations and tablets for treatment or prevention of neurological disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRETT, STEPHANIE ELIZABETH;GINDY, MARIAN E.;LI, LI;AND OTHERS;SIGNING DATES FROM 20170502 TO 20170505;REEL/FRAME:047459/0488

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

AS Assignment

Owner name: MERCK SHARP & DOHME LLC, NEW JERSEY

Free format text: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:060075/0913

Effective date: 20220407

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE